China’s Hainan Haiyao, a Shenzhen-listed drug maker and distributor, plans to invest RMB122 million ($20 million) in a pharma-focused joint venture with several venture capital firms....
Greater China | 10 Mar 2014 |
IKang Healthcare Group - the Chinese healthcare services provider whose backers include Singapore sovereign wealth fund GIC Private, Goldman Sachs and NewQuest Asia - is planning to raise up to $150 million in an initial public offering on the Nasdaq...
Exits | 05 Mar 2014 |
Bayer has agreed to buy Dihon Pharmaceutical Group, a manufacturer of herbal traditional Chinese medicines (TCM). The acquisition facilitates the exit of Legend Capital, an investor in Dihon since 2010.
Greater China | 28 Feb 2014 |
Australian radiology provider I-Med Network Radiology is being sold by its hedge fund owners to a consortium led by EQT Partners.
Australasia | 25 Feb 2014 |
Bamboo Finance, a European private equity firm that focuses on investments benefiting low-income communities in emerging markets, and early stage investor Saama Capital have together taken part in a Series B round of funding for Indian healthcare provider...
South Asia | 20 Feb 2014 |
CITIC Private Equity has held talks about potentially increasing its stake in Singapore-listed portfolio company Biosensors International, the medical device maker said on Wednesday.
Greater China | 20 Feb 2014 |
CITIC Private Equity is said to be looking to buy full control of its Singapore-listed portfolio company Biosensors International, a medical device maker.
Greater China | 19 Feb 2014 |
TPG Capital and Fosun Industrial have teamed up with the CEO of Chinese healthcare provider Chindex International have won board approval to privatize the NASDAQ-listed company. The deal values Chindex at approximately $369 million.
Buyouts | 18 Feb 2014 |
Japan Asian Investment Corporation (JAIC) and Nippon Venture Capital have together led a $9.2 million Series D round of investment in Tokyo-based biotech firm Regimmune Corporation.
North Asia | 17 Feb 2014 |
Private equity impact investments in India totaled $390 million across 80 deals last year – comprising 23% of all PE transactions in the country - says Bangalore-based financial advisor Unitus Capital.
South Asia | 14 Feb 2014 |
Eleven Biotherapeutics, a US biopharma company firm backed by Japan’s Jafco Ventures, has raised $50 million through its NASDAQ IPO – short of the $69 million initially sought.
Venture | 12 Feb 2014 |
STIC Investments backed Access Bio when the Korean-led malaria testing technology player wanted to buy key components and expand output. Now KOSDAQ-listed, the company has its eye on specialty diagnostics
Expansion | 12 Feb 2014 |
China-focused BVCF has committed $2 million in a Series A round of funding for Jaguar Animal Health, a veterinary drugs developer, with another $3 million to come by the end of the month.
Greater China | 06 Feb 2014 |
Envision Pharma Group, a scientific communication company backed by US-based private equity firm The Halifax Group, has acquired Australian medical writing firm ProSribe in a move to expand its Asian footprint.
Australasia | 06 Feb 2014 |
Updating your subscription status
Join us at the 11th Annual AVCJ Private Equity & Venture Australia and New Zealand Forum on 5-7 March at the Four Seasons Hotel in Sydney to find out how funds of varying size are raising capital, sourcing deals and exits, as well as all you need to know to effectively navigate Australasia's changing alternative asset landscape.
After a decade-long mining boom the economy is experiencing a loss of momentum and the resulting deal flow reduction and lack of value in the market means GPs are chasing many of the same acquisition targets. That said, the exit market is recovering with both IPOs and M&A activity picking up, and an increase in LPs appetite for the asset class, and the recent government change means that the industry is cautiously optimistic for the future and expecting a rise in activity over the next 12 months.
5-7 March 2014, Four Seasons Hotel, Sydney